186 related articles for article (PubMed ID: 38216400)
1. Predictive and prognostic molecular biomarkers in lymphomas.
Iorgulescu JB; Medeiros LJ; Patel KP
Pathology; 2024 Mar; 56(2):239-258. PubMed ID: 38216400
[TBL] [Abstract][Full Text] [Related]
2. A genetic profiling guideline to support diagnosis and clinical management of lymphomas.
Sánchez-Beato M; Méndez M; Guirado M; Pedrosa L; Sequero S; Yanguas-Casás N; de la Cruz-Merino L; Gálvez L; Llanos M; García JF; Provencio M
Clin Transl Oncol; 2024 May; 26(5):1043-1062. PubMed ID: 37672206
[TBL] [Abstract][Full Text] [Related]
3. New developments in non-Hodgkin lymphoid malignancies.
Ganapathi KA; Brown LE; Prakash S; Bhargava P
Pathology; 2021 Apr; 53(3):349-366. PubMed ID: 33685720
[TBL] [Abstract][Full Text] [Related]
4. [Molecular abnormalities in lymphomas].
Delsol G
Bull Cancer; 2010 Nov; 97(11):1347-64. PubMed ID: 21084243
[TBL] [Abstract][Full Text] [Related]
5. MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR.
Pott C; Brüggemann M; Ritgen M; van der Velden VHJ; van Dongen JJM; Kneba M
Methods Mol Biol; 2019; 1956():199-228. PubMed ID: 30779036
[TBL] [Abstract][Full Text] [Related]
6. [R.E.A.L. classification of non-Hodgkin lymphoma from the clinico-oncologic viewpoint].
Meusers P; Brittinger G
Praxis (Bern 1994); 1998 Jun; 87(23):793-800. PubMed ID: 9654985
[TBL] [Abstract][Full Text] [Related]
7. An update on genetic aberrations in T-cell neoplasms.
Parilla M; Quesada AE; Medeiros LJ; Thakral B
Pathology; 2023 Apr; 55(3):287-301. PubMed ID: 36801152
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms.
Onaindia A; Medeiros LJ; Patel KP
Mod Pathol; 2017 Oct; 30(10):1338-1366. PubMed ID: 28664939
[TBL] [Abstract][Full Text] [Related]
9. The World Health Organization classification of malignant lymphoma: incidence and clinical prognosis in HTLV-1-endemic area of Fukuoka.
Ohshima K; Suzumiya J; Kikuchi M
Pathol Int; 2002 Jan; 52(1):1-12. PubMed ID: 11940200
[TBL] [Abstract][Full Text] [Related]
10. Distribution and ZAP-70 expression of WHO lymphoma categories in Shanxi, China: a review of 447 cases using a tissue microarray technique.
Wang J; Young L; Win W; Taylor CR
Appl Immunohistochem Mol Morphol; 2005 Dec; 13(4):323-32. PubMed ID: 16280661
[TBL] [Abstract][Full Text] [Related]
11. Pathology consultation on intermediate-to-large B-cell lymphomas.
Montgomery ND; Fedoriw Y
Am J Clin Pathol; 2014 Mar; 141(3):305-17. PubMed ID: 24515757
[TBL] [Abstract][Full Text] [Related]
12. ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia.
Ladetto M; Buske C; Hutchings M; Dreyling M; Gaidano G; Le Gouill S; Luminari S; Pott C; Zamò A; Zucca E;
Ann Oncol; 2016 Dec; 27(12):2149-2160. PubMed ID: 27701070
[TBL] [Abstract][Full Text] [Related]
13. Expression profiles of MYC protein and MYC gene rearrangement in lymphomas.
Chisholm KM; Bangs CD; Bacchi CE; Molina-Kirsch H; Cherry A; Natkunam Y
Am J Surg Pathol; 2015 Mar; 39(3):294-303. PubMed ID: 25581730
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive histopathological diagnostics of aggressive B-cell lymphomas based on the updated criteria of the World Health Organisation's 2017 classification.
Szumera-Ciećkiewicz A; Rymkiewicz G; Grygalewicz B; Jesionek-Kupnicka D; Gruchała A; Ziarkiewicz-Wróblewska B; Gałązka K; Reszeć J; Borg K; Prochorec-Sobieszek M
Pol J Pathol; 2018; 69(1):1-19. PubMed ID: 29895122
[TBL] [Abstract][Full Text] [Related]
15. [Pathology of malignant lymphomas--clarity instead of confusion].
Mueller-Garamvölgyi E; Perren A; Schmitt A
Ther Umsch; 2010 Oct; 67(10):497-500. PubMed ID: 20886454
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies.
Cani AK; Soliman M; Hovelson DH; Liu CJ; McDaniel AS; Haller MJ; Bratley JV; Rahrig SE; Li Q; Briceño CA; Tomlins SA; Rao RC
Mod Pathol; 2016 Jul; 29(7):685-97. PubMed ID: 27102345
[TBL] [Abstract][Full Text] [Related]
17. Genetics and Diagnostic Approach to Lymphoblastic Leukemia/Lymphoma.
Afkhami M; Ally F; Pullarkat V; Pillai RK
Cancer Treat Res; 2021; 181():17-43. PubMed ID: 34626353
[TBL] [Abstract][Full Text] [Related]
18. BCR-ABL1-like B-Lymphoblastic Leukemia/Lymphoma with FOXP1-ABL1 Rearrangement: Comprehensive Laboratory Identification Allowing Tyrosine Kinase Inhibitor Use.
Yenamandra AK; Kaviany S; Borinstein SC; Friedman DL; Kovach AE
Lab Med; 2019 Oct; 50(4):401-405. PubMed ID: 30938769
[TBL] [Abstract][Full Text] [Related]
19. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.
Li S; Lin P; Fayad LE; Lennon PA; Miranda RN; Yin CC; Lin E; Medeiros LJ
Mod Pathol; 2012 Jan; 25(1):145-56. PubMed ID: 22002575
[TBL] [Abstract][Full Text] [Related]
20. [Grey zone lymphomas: limitations of the classification of aggressive B-cell lymphomas].
Ott MM; Horn H; Rosenwald A; Ott G
Pathologe; 2013 May; 34(3):225-32. PubMed ID: 23494279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
